Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
-
Ardeshir A, O'Hagan D, Mehta I, Shandilya S, Hopkins LLJ, Adamson L, Kuroda MJ, Hahn PA, da Costa LAB, Fuchs SP, Martinez-Navio JM, Gardner MR, Van Rompay KKA, Magnani DM, Lifson JD, Gao G, Farzan M, Desrosiers RC, Das J, Martins MA. Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature. 2025 Sep; 645(8082):1020-1028.
-
Matsuda K, Harrison M, Wettstein E, Pederson J, Pullano AA, Bolkhovitinov L, Kim B, Steinberg I, Griesman T, Stuccio S, Rogan D, Patamawenu A, Shofner T, Wright NE, Webber JD, Van't Veer F, Roenicke R, Koory E, Roeder PM, Ober E, Leach B, Tsybovsky Y, Stephens T, Del Moral-Sanchez I, Bontjer I, McGinnes-Cullen LW, Chu E, Liang J, Torres JL, Lin RN, Tran AS, Dziubla G, Serebryannyy L, Narpala S, Lin B, Castro M, Ozorowski G, Ward AB, Sanders RW, Kwong PD, Guenaga J, Wyatt R, Morrison T, Connors M. Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response. Nat Commun. 2025 Jun 03; 16(1):5162.
-
Dankwa S, Kosman C, Dennis M, Giorgi EE, Vuong K, Pahountis I, Garza A, Binuya C, McCarthy J, Mayer BT, Ngo JT, Enemuo CA, Carnathan DG, Stanfield-Oakley S, Berendam SJ, Weinbaum C, Engelman K, Magnani DM, Chan C, Ferrari G, Silvestri G, Amara RR, Chahroudi A, Permar SR, Fouda GG, Goswami R. A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. PLoS One. 2024; 19(11):e0312411.
-
Zikos J, Webb GM, Wu HL, Reed JS, Watanabe J, Usachenko JL, Shaqra AM, Schiffer CA, Van Rompay KKA, Sacha JB, Magnani DM. FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques. MAbs. 2024 Jan-Dec; 16(1):2406788.
-
Marchitto L, Richard J, Pr?vost J, Tauzin A, Yang D, Chiu T-J, Chen H-C, D?az-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussi?res G, Anand SP, Dionne K, B?langer ?, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB, Finzi A. The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity. J Virol. 2024 Oct 22; 98(10):e0101624.
-
Wang S, Chan KW, Wei D, Ma X, Liu S, Hu G, Park S, Pan R, Gu Y, Nazzari AF, Olia AS, Xu K, Lin BC, Louder MK, McKee K, Doria-Rose NA, Montefiori D, Seaman MS, Zhou T, Kwong PD, Arthos J, Kong XP, Lu S. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains. Nat Commun. 2024 May 21; 15(1):4301.
-
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, De Rosa SC, Morris DE, Wang S, Seaman MS, Montefiori DC, Ferrari G, Tomaras GD, Kublin JG, Corey L, Lu S. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. Lancet HIV. 2024 May; 11(5):e285-e299.
-
Verdejo-Torres O, Vargas-Pavia T, Fatima S, Clapham PR, Duenas-Decamp MJ. Implications of the 375W mutation for HIV-1 tropism and vaccine development. J Virol. 2024 01 23; 98(1):e0152223.
-
Costanzo MC, Paquin-Proulx D, Schuetz A, Akapirat S, Shubin Z, Kim D, Wieczorek L, Polonis VR, Trinh HV, Rao M, Anenia H, Barrera MD, Boeckelman J, Nails B, Thapa P, Zemil M, Sacdalan C, Kroon E, Kaewboon B, Tipsuk S, Jongrakthaitae S, Gurunathan S, Sinangil F, Kim JH, Robb ML, Ake JA, O'Connell RJ, Pitisutthithum P, Nitayaphan S, Chariyalertsak S, Eller MA, Phanuphak N, Vasan S. ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone. JCI Insight. 2023 05 08; 8(9).
-
Li H, Wang S, Hu G, Zhang L, Liu S, Lu S. DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. Emerg Microbes Infect. 2021 Dec; 10(1):833-841.